Clin Psychopharmacol Neurosci.
2020 Nov;18(4):641. 10.9758/cpn.2020.18.4.641.
Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
- Affiliations
-
- 1Department of Psychiatry, Korea University College of Medicine, Seoul, Korea
- 2Department of Psychiatry,College of Medicine, The Catholic University of Korea, Seoul, Korea
- 3International Health Care Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 4Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
- 5Global Medical Education, New York, NY, USA
- 6Department of Biomedical and Neuromotor Sciences, Psychiatric Section, University of Bologna, Bologna, Italy
- 7Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2508991
- DOI: http://doi.org/10.9758/cpn.2020.18.4.641
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
- Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
- Current Update on Transcranial Direct Current Stimulation as Treatment for Major Depressive Disorder
- Effect of Self-administered Transcranial Direct Stimulation in Patients with Major Depressive Disorder: A Randomized, Single-blinded Clinical Trial
- Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
